Otsuka Of Japan Joins Other MNCs And Considers R&D Investment Deal With Korean Ministry
This article was originally published in PharmAsia News
Executive Summary
Japan's Otsuka Pharmaceutical is considering signing a memorandum of understating regarding a research and development investment deal with the Korean Ministry of Health, Welfare and Family Affairs, the Korean agency disclosed May 29. Currently, Novartis Korea is in the process of signing a MOU in investing $100 million in R&D with the ministry, and Korean subsidiaries of AstraZeneca and Pfizer have signed the MOUs. Besides Ostuka, Sanofi-Aventis is also considering a similar investment. Korea requires a minimum of $100 million in such R&D investment deals. (Click here for more - Japanese language
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.